High-resolution genomic profiling to predict 10-year overall survival in node-negative breast cancer

Cancer Genetics and Cytogenetics

Volumn 198, Issue 2, 2010, Pages 79-89

  Möllerström, Elin ^a   Delle, Ulla ^a   Danielsson, Anna ^a   Parris, Toshima ^a   Olsson, Björn ^b   Karlsson, Per ^c   Helou, Khalil ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF SKÖVDE   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; GENOMIC RNA;

ADULT; ARTICLE; BREAST CANCER; CADAVER; CANCER SURVIVAL; CHROMOSOME 1Q; CHROMOSOME 21P; CHROMOSOME 8P; CHROMOSOME LOSS; CHROMOSOME XP; CLINICAL ASSESSMENT; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE IDENTIFICATION; GENE LOCATION; GENETIC DIFFERENCE; GENETIC GAIN; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; OVERALL SURVIVAL; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TUMOR GROWTH;

EID: 77950856355     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2009.12.012     Document Type: Article

References (30)

1. Eifel P., Axelson J.A., Costa J., Crowley J., Curran W.J., Deshler A., Fulton S., Hendricks C.B., Kemeny M., Kornblith A.B., Louis T.A., Markman M., Mayer R., Roter D. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001, 93:979-989.
2. Michaelson J.S., Silverstein M., Sgroi D., Cheongsiatmoy J.A., Taghian A., Powell S., Hughes K., Comegno A., Tanabe K.K., Smith B. The effect of tumor size and lymph node status on breast carcinoma lethality. Cancer 2003, 98:2133-2143.
3. Goldhirsch A., Wood W.C., Gelber R.D., Coates A.S., Thurlimann B., Senn H.J. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007, 18:1133-1144. [Erratum in: Ann Oncol 2007;18:1917].
4. Karlsson E., Delle U., Danielsson A., Olsson B., Abel F., Karlsson P., Helou K. Gene expression variation to predict 10-year survival in lymph-node-negative breast cancer. BMC Cancer 2008, 8:254.
5. Tsumagari K., Chijiiwa K., Nagai H., Makita M., Kasumi F., Akiyama F., Sakamoto G., Miki Y. Postoperative prognosis of node-negative breast cancers predicted by gene-expression profiling on a cDNA microarray of 25,344 genes. Breast Cancer 2005, 12:166-177.
6. Wang Y., Klijn J.G., Zhang Y., Sieuwerts A.M., Look M.P., Yang F., Talantov D., Timmermans M., Meijer-van Gelder M.E., Yu J., Jatkoe T., Berns E.M., Atkins D., Foekens J.A. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679.
7. van't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T., Schreiber G.J., Kerkhoven R.M., Roberts C., Linsley P.S., Bernards R., Friend S.H. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
8. Dellas A., Torhorst J., Schultheiss E., Mihatsch M.J., Moch H. DNA sequence losses on chromosomes 11p and 18q are associated with clinical outcome in lymph node-negative ductal breast cancer. Clin Cancer Res 2002, 8:1210-1216.
9. Hermsen M.A., Baak J.P., Meijer G.A., Weiss J.M., Walboomers J.W., Snijders P.J., van Diest P.J. Genetic analysis of 53 lymph node-negative breast carcinomas by CGH and relation to clinical, pathological, morphometric, and DNA cytometric prognostic factors. J Pathol 1998, 186:356-362.
10. Isola J.J., Kallioniemi O.P., Chu L.W., Fuqua S.A., Hilsenbeck S.G., Osborne C.K., Waldman F.M. Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol 1995, 147:905-911.
11. Janssen E.A., Baak J.P., Guervos M.A., van Diest P.J., Jiwa M., Hermsen M.A. In lymph node-negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter, and oestrogen receptor. J Pathol 2003, 201:555-561.
12. Karlsson E., Danielsson A., Delle U., Olsson B., Karlsson P., Helou K. Chromosomal changes associated with clinical outcome in lymph node-negative breast cancer. Cancer Genet Cytogenet 2007, 172:139-146.
13. Jönsson G., Staaf J., Olsson E., Heidenblad M., Vallon-Christersson J., Osoegawa K., de Jong P., Oredsson S., Ringnér M., Höglund M., Borg A. High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. Genes Chromosomes Cancer 2007, 46:543-558.
14. Saal L.H., Troein C., Vallon-Christersson J., Gruvberger S., Borg A., Peterson C. BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data. Genome Biol 2002, 3. SOFTWARE0003.1-3.6.
15. Osterberg L., Levan K., Partheen K., Delle U., Olsson B., Sundfeldt K., Horvath G. Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas. BMC Cancer 2009, 9:368.
16. Gunnarsson R., Staaf J., Jansson M., Ottesen A.M., Göransson H., Liljedahl U., Ralfkiaer U., Mansouri M., Buhl A.M., Smedby K.E., Hjalgrim H., Syvänen A.C., Borg A., Isaksson A., Jurlander J., Juliusson G., Rosenquist R. Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia: a comparative study of four differently designed, high resolution microarray platforms. Genes Chromosomes Cancer 2008, 47:697-711.
17. Gehan E.A. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 1965, 52:203-223.
18. Chin K., DeVries S., Fridlyand J., Spellman P.T., Roydasgupta R., Kuo W.L., Lapuk A., Neve R.M., Qian Z., Ryder T., Chen F., Feiler H., Tokuyasu T., Kingsley C., Dairkee S., Meng Z., Chew K., Pinkel D., Jain A., Ljung B.M., Esserman L., Albertson D.G., Waldman F.M., Gray J.W. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006, 10:529-541.
19. Bergamaschi A., Kim Y.H., Wang P., Sørlie T., Hernandez-Boussard T., Lonning P.E., Tibshirani R., Børresen-Dale A.L., Pollack J.R. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 2006, 45:1033-1040.
20. Fridlyand J., Snijders A.M., Ylstra B., Li H., Olshen A., Segraves R., Dairkee S., Tokuyasu T., Ljung B.M., Jain A.N., McLennan J., Ziegler J., Chin K., Devries S., Feiler H., Gray J.W., Waldman F., Pinkel D., Albertson D.G. Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer 2006, 6:96.
21. Hicks J., Krasnitz A., Lakshmi B., Navin N.E., Riggs M., Leibu E., Esposito D., Alexander J., Troge J., Grubor V., Yoon S., Wigler M., Ye K., Børresen-Dale A.L., Naume B., Schlicting E., Norton L., Hägerström T., Skoog L., Auer G., Månér S., Lundin P., Zetterberg A. Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res 2006, 16:1465-1479.
22. Naylor T.L., Greshock J., Wang Y., Colligon T., Yu Q.C., Clemmer V., Zaks T.Z., Weber B.L. High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization. Breast Cancer Res 2005, 7:R1186-R1198.
23. Climent J., Martinez-Climent J.A., Blesa D., Garcia-Barchino M.J., Saez R., Sánchez-Izquierdo D., Azagra P., Lluch A., Garcia-Conde J. Genomic loss of 18p predicts an adverse clinical outcome in patients with high-risk breast cancer. Clin Cancer Res 2002, 8:3863-3869.
24. Hislop R.G., Pratt N., Stocks S.C., Steel C.M., Sales M., Goudie D., Robertson A., Thompson A.M. Karyotypic aberrations of chromosomes 16 and 17 are related to survival in patients with breast cancer. Br J Surg 2002, 89:1581-1586.
25. Jones C., Ford E., Gillett C., Ryder K., Merrett S., Reis-Filho J.S., Fulford L.G., Hanby A., Lakhani S.R. Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. Clin Cancer Res 2004, 10(18 Pt 1):5988-5997.
26. Rennstam K., Ahlstedt-Soini M., Baldetorp B., Bendahl P.O., Borg A., Karhu R., Tanner M., Tirkkonen M., Isola J. Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis: a study of 305 tumors by comparative genomic hybridization. Cancer Res 2003, 63:8861-8868.
27. Seute A., Sinn H.P., Schlenk R.F., Emig R., Wallwiener D., Grischke E.M., Hohaus S., Döhner H., Haas R., Bentz M. Clinical relevance of genomic aberrations in homogeneously treated high-risk stage II/III breast cancer patients. Int J Cancer 2001, 93:80-84.
28. Zudaire I., Odero M.D., Caballero C., Valenti C., Martínez-Penuela J.M., Isola J., Calasanz M.J. Genomic imbalances detected by comparative genomic hybridization are prognostic markers in invasive ductal breast carcinomas. Histopathology 2002, 40:547-555.
29. Han W., Han M.R., Kang J.J., Bae J.Y., Lee J.H., Bae Y.J., Lee J.E., Shin H.J., Hwang K.T., Hwang S.E., Kim S.W., Noh D.Y. Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer. BMC Cancer 2006, 6:92.
30. Hwang K.T., Han W., Cho J., Lee J.W., Ko E., Kim E.K., Jung S.Y., Jeong E.M., Bae J.Y., Kang J.J., Yang S.J., Kim S.W., Noh D.Y. Genomic copy number alterations as predictive markers of systemic recurrence in breast cancer. Int J Cancer 2008, 123:1807-1815.